Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc. on August 4, 2021, reporting an event that occurred on July 30, 2021. The Company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol ALZN.
Key Financial Metrics and Transaction Details
The filing discloses a specific financing transaction rather than periodic financial results. Key metrics related to this event include:
- Total Investment Amount: $2,000,000
- Investor: Digital Power Lending, LLC (DPL), a wholly-owned subsidiary of Ault Global Holdings, Inc.
- Common Stock Issued: 1,333,333 shares at $1.50 per share.
- Warrants Issued: Warrants to acquire 666,667 shares of common stock with an exercise price of $3.00 per share.
- Agreement Reference: Securities Purchase Agreement dated March 9, 2021.
The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions outside of this specific transaction.
Material Changes
The material change reported is the receipt of additional capital pursuant to a pre-existing agreement. This transaction increases the Company's cash position by $2,000,000 and increases the number of outstanding shares and potential dilution through the issuance of new common stock and warrants.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that statements regarding future operating results involve risks and uncertainties. No specific financial guidance, outlook, or management commentary regarding future performance was provided in this document. The filing explicitly states that the information is not intended to constitute material investor information not otherwise publicly available beyond the press release incorporated by reference.
Investor Verification Checklist
- Verify the terms of the Securities Purchase Agreement dated March 9, 2021, to understand the full scope of obligations to DPL.
- Confirm the impact of the 1,333,333 new shares and 666,667 warrants on total share count and potential dilution.
- Review the press release (Exhibit 99.1) for any additional context on the use of proceeds not detailed in the 8-K text.
- Check subsequent filings for the Company's overall cash position and burn rate to assess the longevity of this capital infusion.